Incyte Posts $784.8M Q3 Loss on $1.23B Vega IPR&D Charge as Revenue Climbs 14%
INCY sits 32% above its 52-week low of $88.2 on elevated volume (1.9× avg).
Summary
Incyte's Q3 2026 revenue rose to $1.557 billion from $1.366 billion, but a $1.232 billion one-time charge on the $1.25 billion Vega acquisition drove a $784.8 million net loss, or $3.86 per share. Nine-month operating cash flow fell to $201.7 million, leaving $3.9 billion in cash and securities.
Key Events · Earnings and Guidance · INCY
-
Vega Deal Drives $1.23B R&D Charge
The July 6, 2026 acquisition of Vega Therapeutics for $1.25 billion in cash was accounted for as an asset acquisition, so $1.232 billion of acquired IPR&D for latarcibart was expensed immediately, producing a Q3 net loss of $784.8 million, or $3.86 per share.
-
Revenue Grows 14% on JAKAFI and OPZELURA
Q3 total revenues were $1.557 billion versus $1.366 billion a year earlier; JAKAFI net sales reached $826.5 million and OPZELURA $254.9 million, with NIKTIMVO at $67.4 million and ZYNYZ at $58.3 million.
-
Operating Cash Flow Falls on Acquisition
Nine-month operating cash flow was $201.7 million versus $870.2 million in 2025, which the company attributes primarily to the Vega cash consideration; cash, equivalents and marketable securities totaled $3.9 billion at September 30, 2026.
-
Balance Sheet Stays Unlevered
No borrowings or letters of credit were outstanding on the $500 million revolver maturing June 2027, and the company was in compliance with all covenants.
Analysis · INCY · Industrial Applications And Services
The headline loss reflects an accounting charge, not a cash burn. Acquiring Vega for $1.25 billion in cash forced Incyte to expense $1.232 billion of acquired in-process R&D immediately, because the latarcibart program has no alternative future use. Strip that out and the commercial business grew: total revenue reached $1.557 billion versus $1.366 billion a year ago, with JAKAFI sales up to $826.5 million. The real cost shows up on the balance sheet and in cash flow. Operating cash flow for the nine months fell to $201.7 million from $870.2 million, largely because of the Vega payment, leaving $3.9 billion of cash and securities and no revolver borrowings. The bet is that latarcibart, a Phase 3 von Willebrand disease antibody with Breakthrough and rare pediatric designations, replaces revenue that begins eroding when JAKAFI patents expire in 2028.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INCY was trading at $116.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $88.20 to $132.60. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.